Odronextamab Demonstrates Durable Complete Responses in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR-T Therapy: Outcomes from the ELM-1 Study
Jennifer L. Crombie(Dana-Farber Cancer Institute), Steve M Ansell(Mayo Clinic in Arizona), Susan O’Brien(University of California, Irvine), Jon Arnason(Beth Israel Deaconess Medical Center), Srikanth Ambati(Regeneron (United States)), John N. Allan(Cornell University), Jeffrey A. Barnes(Harvard University), Hesham Mohamed(Bristol-Myers Squibb (United States)), Matthew J. Matasar(Rutgers, The State University of New Jersey), Uri Abadi(Tel Aviv University), Neta Goldschmidt(National Institutes of Health), Jean‐Marie Michot(Institut Gustave Roussy), Max S. Topp(Universitätsklinikum Würzburg), Min Zhu(Eye & ENT Hospital of Fudan University), Irit Avivi Mazza, Jessica Cai(Regeneron (United States)), Jurriaan Brouwer‐Visser(Montefiore Medical Center), Aafia Chaudhry(Regeneron (United States)), Dina M. Flink(Progenics Pharmaceuticals (United States))
Cited by 8
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k